CRISPR/Cas9 disruption of EpCAM Exon 2 results in cell-surface expression of a truncated protein targeted by an EpCAM specific T cell engager

por Bagheri, Andisheh, Culp, Patricia A., DuBridge, Robert B., Chen, Tseng-hui Timothy
Publicado 2022

COBRA™: a highly potent conditionally active T cell engager engineered for the treatment of solid tumors

por Panchal, Anand, Seto, Pui, Wall, Russell, Hillier, Brian J., Zhu, Ying, Krakow, Jessica, Datt, Aakash, Pongo, Elizabeth, Bagheri, Andisheh, Chen, Tseng-Hui T., Degenhardt, Jeremiah D., Culp, Patricia A., Dettling, Danielle E., Vinogradova, Maia V., May, Chad, DuBridge, Robert B.
Publicado 2020